Ernexa Therapeutics Inc. is a preclinical-stage synthetic allogeneic iMSC (iPSC-derived mesenchymal stem cell) therapy company. Its lead candidate, ERNA-101, consists of IL-7 and IL-15-secreting iMSCs designed to target platinum-resistant ovarian cancer by delivering pro-inflammatory factors to the tumor microenvironment. A second candidate, ERNA-201, targets autoimmune disorders such as rheumatoid arthritis. The company in-licenses its core technology from Factor Bioscience Limited and collaborates with MD Anderson Cancer Center.
expected 2026-12-16
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-13 | 2025-12-31 | 0001493152-26-010102 | EDGAR | 72K words |
| 2025-03-12 | 2024-12-31 | 0001493152-25-010051 | EDGAR | 74K words |
| 2024-03-14 | 2023-12-31 | 0001140361-24-013254 | EDGAR | 77K words |
| 2023-03-20 | 2022-12-31 | 0001140361-23-012418 | EDGAR | 84K words |
| 2022-04-15 | 2021-12-31 | 0001140361-22-014764 | EDGAR | — |
| 2021-03-11 | 2020-12-31 | 0001493152-21-005827 | EDGAR | — |
| 2020-03-19 | 2019-12-31 | 0001493152-20-004343 | EDGAR | — |
| 2019-03-22 | 2018-12-31 | 0001493152-19-003770 | EDGAR | — |
| 2018-03-09 | 2017-12-31 | 0001493152-18-003164 | EDGAR | — |
| 2017-03-09 | 2016-12-31 | 0001493152-17-002280 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-06 | 2026-06-30 | 0001493152-26-036424 | EDGAR | 24K words |
| 2025-11-07 | 2025-09-30 | 0001493152-25-021287 | EDGAR | 24K words |
| 2025-08-13 | 2025-06-30 | 0001493152-25-011910 | EDGAR | 22K words |
| 2025-05-07 | 2025-03-31 | 0001641172-25-009044 | EDGAR | 18K words |
| 2024-11-12 | 2024-09-30 | 0001493152-24-044841 | EDGAR | 29K words |
| 2024-08-13 | 2024-06-30 | 0001493152-24-031639 | EDGAR | 27K words |
| 2024-05-14 | 2024-03-31 | 0001140361-24-026010 | EDGAR | 24K words |
| 2023-11-13 | 2023-09-30 | 0001140361-23-052742 | EDGAR | 27K words |
| 2023-08-11 | 2023-06-30 | 0001140361-23-039283 | EDGAR | 25K words |
| 2023-05-11 | 2023-03-31 | 0001140361-23-024180 | EDGAR | 19K words |
| 2022-11-14 | 2022-09-30 | 0001140361-22-041399 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0001140361-22-029251 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-09-16 | 0001493152-26-042963 | EDGAR | 0K words |
| 2026-09-16 | 0001493152-26-042934 | EDGAR | 1K words |
| 2026-03-20 | 0001493152-26-011922 | EDGAR | 1K words |
| 2026-02-26 | 0001493152-26-008182 | EDGAR | 0K words |
| 2026-02-11 | 0001493152-26-006227 | EDGAR | 1K words |
| 2025-12-11 | 0001493152-25-027167 | EDGAR | 0K words |
| 2025-07-07 | 0001641172-25-018009 | EDGAR | 1K words |
| 2025-06-12 | 0001641172-25-014877 | EDGAR | 1K words |
| 2025-06-09 | 0001641172-25-014318 | EDGAR | 1K words |
| 2025-06-02 | 0001641172-25-013249 | EDGAR | 1K words |
374 total filings indexed. 342 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0000748592 |
| Ticker | ERNA |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.ernexatx.com |
| Listed | 2021-03-26 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/ERNA (~200 tokens, structured JSON with cryptographic provenance)